

Dear Pharmacist:

Thank you for registering to dispense THALOMID™ (thalidomide). Your registration card has been received and processed, and your pharmacy is now registered in the **System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.)** Pharmacy Registry. You will receive patient registration forms that must be completed for every new patient receiving THALOMID™ (thalidomide) with your first THALOMID™ (thalidomide) shipment.

Your pharmacy may now dispense prescriptions for THALOMID™ (thalidomide), according to the following procedures:

Dispensing initial prescriptions:

- Note that telephone prescriptions are not permitted with initial prescriptions.
- Do not dispense if prescription was written more than 14 days prior.
- Collect and retain a signed informed consent form.
 - If the patient does not present a completed informed consent form with the prescription, the physician must be notified that the form is mandatory for a prescription to be filled.
 - The physician can order required S.T.E.P.S. program materials by calling 1-888-4-CELGENE.
- Enroll the patient in the S.T.E.P.S. Patient Registry.
 - Complete the patient registration form and supply the information by calling 1-888-4-CELGENE, or by fax to 1-888-475-2672.
- Dispense no more than a 4-week (28-day) supply of THALOMID™ (thalidomide) therapy.
Automatic refill prescriptions are not permitted.

Dispensing subsequent prescriptions:

- Telephone prescriptions are permitted.
- Do not dispense if prescription was written more than 14 days prior.
- Verify patient registry and record subsequent prescriptions.
 - Patient enrollment status must be verified via ~~on-line~~ transmission (BIN 610554 Processor Control BBI, Submitted Group Thalidomide) or by calling 1-888-4-CELGENE.
- Do not dispense THALOMID™ (thalidomide) if more than 7 days remain on the previous prescription.
- Dispense no more than a 4-week (28-day) supply.

THALOMID™ (thalidomide) blister packages must be dispensed intact. The capsules cannot be repackaged.

A monograph that provides important information regarding the risks and benefits of THALOMID™ (thalidomide), as well as prescribing and dispensing guidelines, will be provided to you. This monograph is approved for continuing pharmaceutical education credits upon completion.

To reorder additional patient registration forms, or if you have questions about the procedures required for dispensing THALOMID™ (thalidomide), please call 1-888-4-CELGENE, or fax your inquiry to 1-888-475-2672.

Thank you for helping make certain that THALOMID™ (thalidomide) is made available to your patients in the most responsible fashion. Please see enclosed full Prescribing Information.

Sincerely,

Bruce A. Williams

Vice President, Director of Medical Affairs